| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | HCHOLA3; LDLCQ1; NARC1; Neural apoptosis regulated convertase 1; PC9; PCSK9; Proprotein convertase 9 |
| Entrez GeneID | 255738 |
| WB Predicted band size | Calculated MW: 74 kDa; Observed MW: 62,78 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthesized peptide derived from human PCSK9 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是3-4条关于PCSK9抗体的参考文献摘要：
---
1. **文献名称**: *Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events*
**作者**: Sabatine MS, et al.
**摘要**: 该研究(FOURIER试验)评估了PCSK9抗体evolocumab在高危心血管疾病患者中的效果。结果显示，与安慰剂相比，evolocumab显著降低LDL-C水平约60%，并减少15%的主要心血管事件风险，且安全性良好(新英格兰医学期刊，2017)。
2. **文献名称**: *Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome*
**作者**: Schwartz GG, et al.
**摘要**: ODYSSEY Outcomes试验发现，PCSK9抗体alirocumab可降低急性冠脉综合征患者的LDL-C水平，并在4年随访中减少15%的MACE(主要心血管不良事件)风险，尤其对基线LDL-C≥100 mg/dL的患者效果更显著(新英格兰医学期刊，2018)。
3. **文献名称**: *PCSK9: A Key Modulator of LDL Metabolism and Target for Therapeutic Inhibition*
**作者**: Seidah NG, et al.
**摘要**: 该综述阐明了PCSK9蛋白通过降解LDL受体调控胆固醇代谢的机制，并总结了早期抗体药物(如alirocumab和evolocumab)的临床前和临床试验数据，证明其作为降脂新靶点的潜力(自然综述·药物发现，2003)。
4. **文献名称**: *Long-term Efficacy and Safety of PCSK9 Antibodies: A Meta-analysis*
**作者**: Stroes ES, et al.
**摘要**: 通过汇总多项临床试验数据，研究发现PCSK9抗体长期使用可持续降低LDL-C且耐受性良好，未显著增加严重不良反应(如神经认知功能障碍或糖尿病风险)(循环杂志，2015)。
---
以上文献涵盖了关键临床试验、机制研究及长期安全性分析，反映了PCSK9抗体的核心研究进展。
PCSK9 (proprotein convertase subtilisin/kexin type 9) is a liver-derived protein that regulates cholesterol metabolism by promoting the degradation of low-density lipoprotein receptors (LDLRs) on hepatocytes. Elevated PCSK9 activity reduces LDLR availability, leading to increased circulating LDL cholesterol (LDL-C), a major risk factor for atherosclerotic cardiovascular disease. The discovery of PCSK9's role in cholesterol homeostasis in 2003 spurred interest in therapeutic inhibition. Monoclonal antibodies targeting PCSK9 emerged as a breakthrough, designed to block its interaction with LDLRs, thereby preserving LDLR density and enhancing LDL-C clearance.
The first PCSK9 inhibitors, alirocumab and evolocumab, were approved by the FDA in 2015. These fully humanized antibodies are administered via subcutaneous injection, typically for patients with familial hypercholesterolemia or high cardiovascular risk inadequately controlled by statins. Clinical trials demonstrated reductions in LDL-C by 50-60% and significant decreases in cardiovascular events. Safety profiles are generally favorable, with mild injection-site reactions as the most common side effect.
Despite their efficacy, high costs and accessibility challenges limit widespread use. Ongoing research explores alternative PCSK9-targeting therapies, including oral small molecules and gene-silencing agents. PCSK9 antibodies remain a cornerstone in managing refractory hypercholesterolemia, offering a precision medicine approach to cardiovascular risk reduction.
×
